Prognostic Awareness and Patient-Physician Communication in Malignant Glioma
This study is currently recruiting participants.
(see Contacts and Locations)
Verified October 2014 by Memorial Sloan Kettering Cancer Center.
Sponsor:
Memorial Sloan Kettering Cancer Center.
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center.
ClinicalTrials.gov Identifier:
NCT02023346
First received: December 23, 2013
Last updated: October 31, 2014
Last verified: October 2014
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to learn more about patients with brain tumors understanding of their disease and their communication with their physician. Ultimately, we hope to use these findings to improve communication between patients and their doctors.
| Condition | Intervention |
|---|---|
|
Malignant Glioma |
Behavioral: surveys and cognitive tests |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Prognostic Awareness and Patient-Physician Communication in Malignant Glioma |
Resource links provided by NLM:
Further study details as provided by Memorial Sloan Kettering Cancer Center.:
Primary Outcome Measures:
- measure prognostic awareness [ Time Frame: 2 years ] [ Designated as safety issue: No ]Prognostic awareness (PA) will be measured using the Chochinov Prognostic Awareness Scale. This scale classifies patients into three categories of awareness: full, limited, or no awareness.
| Estimated Enrollment: | 200 |
| Study Start Date: | December 2013 |
| Estimated Primary Completion Date: | December 2015 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
Malignant Glioma patients
This is a cross-sectional study of patients with MG who are admitted to the inpatient Neurology service at MSKCC. We anticipate that participants will be accrued over approximately 18-24 months. All patients with MG admitted to Neurology, except Dr. Eli Diamond's patients and respective caregivers, will be screened for eligibility and willingness to participate in the study.
|
Behavioral: surveys and cognitive tests |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Study Population
Participants will be recruited from the inpatient Neurology service.
Criteria
Inclusion Criteria:
Patient Inclusion Criteria
- Age greater than or equal to 18
- Diagnosis of any WHO grade III or IV glioma
- Admitted to the inpatient Neurology service
- Has had at least one outpatient visit with a neuro-oncologist at MSKCC Fluent in English
Caregiver Inclusion Criteria
- Age greater than or equal to 18
- Identified by the patient as a relative, friend, or partner with whom he or she has a significant relationship and who provides him or her physical or emotional assistance.
- The patient has himself or herself agreed to participate in this study
Exclusion Criteria:
Patient Exclusion Criteria
- A patient will be excluded if the Glasgow Coma Scale is less than 15. The patient must be oriented to self, age, place, and year, and month.
- Aphasia precluding comprehension and verbalization of consent to participate
- Patients who cannot verbally demonstrate their understanding of the risks, benefits, and alternatives to participating in the study. This evaluation will take place for otherwise eligible and willing participants, and it will be performed by the NP or MD clinician who is obtaining informed consent and will be documented in the medical record.
Caregiver Exclusion Criteria
- No eligible caregivers who can complete the brief assessment in person or via telephone will be excluded
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02023346
Please refer to this study by its ClinicalTrials.gov identifier: NCT02023346
Contacts
| Contact: Eli Diamond, MD | 212-639-7576 | ||
| Contact: Lisa DeAngelis, MD | 212-639-7123 |
Locations
| United States, New York | |
| Memoral Sloan Kettering Cancer Center | Recruiting |
| New Yori, New York, United States, 10065 | |
| Contact: Eli Diamond, MD 212-639-7576 | |
| Contact: Lisa DeAngelis, MD 212-639-7123 | |
| Principal Investigator: Eli Diamond, MD | |
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center.
Investigators
| Principal Investigator: | Eli Diamond, MD | Memorial Sloan Kettering Cancer Center. |
More Information
Additional Information:
No publications provided
| Responsible Party: | Memorial Sloan Kettering Cancer Center. |
| ClinicalTrials.gov Identifier: | NCT02023346 History of Changes |
| Other Study ID Numbers: | 13-253 |
| Study First Received: | December 23, 2013 |
| Last Updated: | October 31, 2014 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Memorial Sloan Kettering Cancer Center.:
|
Patient-Physician Communication Brain cancer 13-253 |
Additional relevant MeSH terms:
|
Glioma Neoplasms Neoplasms by Histologic Type Neoplasms, Germ Cell and Embryonal |
Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Neoplasms, Neuroepithelial Neuroectodermal Tumors |
ClinicalTrials.gov processed this record on March 03, 2015